The Cannell Legacy

Charles Cannell engineered the study of Interviewer-respondent interaction. He created conceptual frameworks for understanding the interviewing process and its impact on data quality. He invented methods for observing and recording interview interaction. He pioneered the use of randomized experiments in the survey context. He amalgamated insights from clinical and social psychology, sociology, group dynamics, as well as research on verbal and nonverbal communication to inform his work. This interdisciplinary approach has broadly influenced both interviewing research and practice. In this paper, we review Cannell’s many contributions to the field and his enduring legacy

The Cannell Legacy

Charles Cannell engineered the study of Interviewer-respondent interaction. He created conceptual frameworks for understanding the interviewing process and its impact on data quality. He invented methods for observing and recording interview interaction. He pioneered the use of randomized experiments in the survey context. He amalgamated insights from clinical and social psychology, sociology, group dynamics, as well as research on verbal and nonverbal communication to inform his work. This interdisciplinary approach has broadly influenced both interviewing research and practice. In this paper, we review Cannell’s many contributions to the field and his enduring legacy

The Cannell Legacy

Charles Cannell engineered the study of Interviewer-respondent interaction. He created conceptual frameworks for understanding the interviewing process and its impact on data quality. He invented methods for observing and recording interview interaction. He pioneered the use of randomized experiments in the survey context. He amalgamated insights from clinical and social psychology, sociology, group dynamics, as well as research on verbal and nonverbal communication to inform his work. This interdisciplinary approach has broadly influenced both interviewing research and practice. In this paper, we review Cannell’s many contributions to the field and his enduring legacy

Package Opening: An Evaluation of Opening Tools for the Elderly Population

Opening packages is becoming more difficult with manufacturers making packaging harder to tamper with. Consumers must apply greater force or use tools to aid them in opening. With aging, the amount of force that can be applied reduces considerably which makes it important to view the packaging problem from the perspective of the older population. The objective of the current study was to determine the effectiveness of opening tools in opening different kinds of packages. The study revealed that the tools are mostly ineffective and do not improve performance beyond the use of the hands alone. In addition, the more complex the tool, the less effective the tool was as an aid to open packaging.Yeshttps://us.sagepub.com/en-us/nam/manuscript-submission-guideline

Design and test of an automated version of the modified Jebsen test of hand function using Microsoft Kinect

Abstract Background The present paper describes the design and evaluation of an automated version of the Modified Jebsen Test of Hand Function (MJT) based on the Microsoft Kinect sensor. Methods The MJT was administered twice to 11 chronic stroke subjects with varying degrees of hand function deficits. The test times of the MJT were evaluated manually by a therapist using a stopwatch, and automatically using the Microsoft Kinect sensor. The ground truth times were assessed based on inspection of the video-recordings. The agreement between the methods was evaluated along with the test-retest performance. Results The results from Bland-Altman analysis showed better agreement between the ground truth times and the automatic MJT time evaluations compared to the agreement between the ground truth times and the times estimated by the therapist. The results from the test-retest performance showed that the subjects significantly improved their performance in several subtests of the MJT, indicating a practice effect. Conclusions The results from the test showed that the Kinect can be used for automating the MJT

Multi-centre parallel arm randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based cognitive behavioural approach to managing fatigue in people with multiple sclerosis

Abstract (provisional) Background Fatigue is one of the most commonly reported and debilitating symptoms of multiple sclerosis (MS); approximately two-thirds of people with MS consider it to be one of their three most troubling symptoms. It may limit or prevent participation in everyday activities, work, leisure, and social pursuits, reduce psychological well-being and is one of the key precipitants of early retirement. Energy effectiveness approaches have been shown to be effective in reducing MS-fatigue, increasing self-efficacy and improving quality of life. Cognitive behavioural approaches have been found to be effective for managing fatigue in other conditions, such as chronic fatigue syndrome, and more recently, in MS. The aim of this pragmatic trial is to evaluate the clinical and cost-effectiveness of a recently developed group-based fatigue management intervention (that blends cognitive behavioural and energy effectiveness approaches) compared with current local practice. Methods This is a multi-centre parallel arm block-randomised controlled trial (RCT) of a six session group-based fatigue management intervention, delivered by health professionals, compared with current local practice. 180 consenting adults with a confirmed diagnosis of MS and significant fatigue levels, recruited via secondary/primary care or newsletters/websites, will be randomised to receive the fatigue management intervention or current local practice. An economic evaluation will be undertaken alongside the trial. Primary outcomes are fatigue severity, self-efficacy and disease-specific quality of life. Secondary outcomes include fatigue impact, general quality of life, mood, activity patterns, and cost-effectiveness. Outcomes in those receiving the fatigue management intervention will be measured 1 week prior to, and 1, 4, and 12 months after the intervention (and at equivalent times in those receiving current local practice). A qualitative component will examine what aspects of the fatigue management intervention participants found helpful/unhelpful and barriers to change. Discussion This trial is the fourth stage of a research programme that has followed the Medical Research Council guidance for developing and evaluating complex interventions. What makes the intervention unique is that it blends cognitive behavioural and energy effectiveness approaches. A potential strength of the intervention is that it could be integrated into existing service delivery models as it has been designed to be delivered by staff already working with people with MS. Service users will be involved throughout this research. Trial registration: Current Controlled Trials ISRCTN7651747

Human liver glycogen phosphorylase inhibitors bind at a new allosteric site

AbstractBackground: Glycogen phosphorylases catalyze the breakdown of glycogen to glucose-1-phosphate for glycolysis. Maintaining control of blood glucose levels is critical in minimizing the debilitating effects of diabetes, making liver glycogen phosphorylase a potential therapeutic target.Results: The binding site in human liver glycogen phosphorylase (HLGP) for a class of promising antidiabetic agents was identified crystallographically. The site is novel and functions allosterically by stabilizing the inactive conformation of HLGP. The initial view of the complex revealed key structural information and inspired the design of a new class of inhibitors which bind with nanomolar affinity and whose crystal structure is also described.Conclusions: We have identified the binding site of a new class of allosteric HLGP inhibitors. The crystal structure revealed the details of inhibitor binding, led to the design of a new class of compounds, and should accelerate efforts to develop therapeutically relevant molecules for the treatment of diabetes